A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity

Anti-Cancer Drug Design

Volumn 16, Issue 1, 2001, Pages 1-6

  Wood, E ^a   Crosby, R M ^a   Dickerson, S ^a   Frye, S V ^a   Griffin, R ^a   Hunter, R ^a   Jung, D K ^a   McDonald, O B ^a   McNutt, R ^a   Mahony, W B ^a   Peel, M R ^a   Ray, J ^a   Lackey, K ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

CRaf1 kinase inhibition; Mitogen activated protein kinase; Phenol isostere; Phenol prodrug

Indexed keywords

ANTINEOPLASTIC AGENT; C RAF1 KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHENOL; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DOWN-REGULATION; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INDICATORS AND REAGENTS; MITOGEN-ACTIVATED PROTEIN KINASES; PHENOLS; PRODRUGS; PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; STRUCTURE-ACTIVITY RELATIONSHIP; TNF RECEPTOR-ASSOCIATED FACTOR 3;

ANIMALIA;

EID: 0035196837     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Synthesis and evaluation of some acyloxyethyl mefenamates as possible prodrugs
2. Structure-based inhibitor design for CDK2, a cell cycle controlling protein kinase
3. Raf-1 protein kinase is an integral component of the oncogenic signal cascade shared by epidermal growth factor and platelet-derived growth factor
4. The discovery of potent cRaf1 kinase inhibitors
5. Discovery of a novel class of potent Raf kinase inhibitors: Structure activity relationships
6. A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: High-throughput screening and identification of selective enzyme inhibitors
7. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl: Protein transferase inhibitor
8. Aryl mesylates in metal catalyzed homo- and cross-coupling reactions. 4. Scope and limitations of aryl mesylates in nickel catalyzed cross-coupling reactions
9. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
10. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
11. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase
12. Prodrug approach, in drug design
13. Some perspectives on targeted delivery with prodrugs
14. New colorimetric cytotoxicity assay for anticancerdrug screening
15. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases
16. The synthesis and biological activity of tetrahydroquinoline angiotensin II antagonists containing a substituted biphenyltetrazole group